Scroll to top

Preliminary recommendation by NICE not to include SCENESSE® for reimbursement by NHS England

21 December 2017

CLINUVEL PHARMACEUTICALS LTD today announced that the first draft assessment from England’s National Institute for Health and Care Excellence (NICE) has been published, with SCENESSE® (afamelanotide 16mg) not recommended for reimbursement for the ultra-orphan disorder erythropoietic protoporphyria (EPP), subject to NICE’s final recommendation expected in May 2018. SCENESSE® is the only approved treatment for EPP patients in Europe and is currently under review as a highly specialised technology (HST) in England.

Download PDF for more

We use cookies to give you the best experience.